A new FDA draft describes how in vitro potency and safety data, anchored to clinical evidence, could support variants of individualized genome-editing therapeutics within a defined product boundary.
An FDA draft announced on October 27 addresses how variants of an individualized human genome-editing product could be included in one biologics license application (BLA), and how further variants could be added after approval. Its scope includes products for monogenic diseases with known pathogenic variants, where the product variants are designed to achieve the same editing outcome. The Federal Register notice followed on October 28; comments are due November 27, 2026.
The draft introduces an individualized feature space (IFS): the allowable variation in the product’s genome-editing components. Applicants would define that space and support it with clinical evidence and explicit in vitro activity and safety criteria. Variants that fail those criteria would fall outside it. Variants in a single BLA should share a mechanism of action and intended editing outcome. Other product attributes, such as the formulation, in vivo delivery vehicle and ex vivo cell type, should remain constant across variants.
The NAMs-relevant provisions concern the evidence used to evaluate those variants. Potency assays should quantify how the variable features contribute to product potency, with acceptance criteria based on clinical-study data. For in vivo products, the draft discusses cell-based assays matched to the targeted gene variants. For ex vivo products, it calls for measurement of the editing outcome in the cellular product and assessment of the intended downstream biological change.
A shared product framework would not remove the need to assess each variant’s unintended-editing risks. The draft calls for appropriate target human cells and other relevant human cell types, with assessment of unintended on-target changes, off-target activity and genomic rearrangements. Empirical, computational and sequence-homology evidence would contribute to the risk assessment where applicable.
For a new product variant targeting another pathogenic variant in the same gene, a BLA supplement could use in vitro activity and safety data together with previously submitted clinical evidence, provided it falls within an established IFS. The activity would need to meet a threshold established in clinical studies, and the safety analysis would need to cover the new variant itself. In most cases, the draft envisages adding such variants without a separate clinical study for each, where the established IFS and supporting evidence justify that approach.
The rationale depends on whether the clinically evaluated variants adequately support the proposed range of variation. The proposed framework ties the use of evidence across variants to that supported product boundary. The document remains a draft, marked not for implementation.
Australia’s TGA already considers non-animal evidence in therapeutic-goods assessment. Its October 2026 statement ties acceptance of a NAM to its intended use, human biological relevance, technical performance and reliability, with validation evidence scaled to the consequences of a wrong conclusion.
A 1 October joint statement from medicines regulators urges validated non-animal methods across the human-medicine lifecycle, with particular emphasis on batch-release testing. Implementation remains with national and regional authorities.
